Contact
searchSearch
HMP Global
Login

Quizzes

Quiz
INCB057643 Therapy for R/R Myelofibrosis
09/26/2025
True or False: The small-molecular BET inhibitor INCB057643 demonstrated promising clinical activity and tolerability both as a monotherapy and combined with ruxolitinib for patients with relapsed/refractory myelofibrosis.
True or False: The small-molecular BET inhibitor INCB057643 demonstrated promising clinical activity and tolerability both as a monotherapy and combined with ruxolitinib for patients with relapsed/refractory myelofibrosis.
True or False: The...
09/26/2025
Oncology
Quiz
Epcoritamab Plus R-ICE for R/R DLBCL
09/26/2025
True or False: According to results from the EPCORE NHL-2 clinical trial, the addition of epcoritamab to standard R-ICE therapy demonstrated high overall and complete response rates among patients with R/R DLBCL eligible for autologous stem...
True or False: According to results from the EPCORE NHL-2 clinical trial, the addition of epcoritamab to standard R-ICE therapy demonstrated high overall and complete response rates among patients with R/R DLBCL eligible for autologous stem...
True or False: According to...
09/26/2025
Oncology
Quiz
Novel Antibody-Drug Conjugate MRG002 Payload
09/25/2025
Do you know the payload for the novel antibody-drug conjugate MRG002? Take our quick quiz to find out!
Do you know the payload for the novel antibody-drug conjugate MRG002? Take our quick quiz to find out!
Do you know the payload for the...
09/25/2025
Oncology
Quiz
Amulirafusp Alfa Plus Lenalidomide for R/R FL
09/24/2025
True or False: According to a phase 2 trial, the combination of amulirafusp alfa and lenalidomide demonstrated encouraging early clinical activity and an acceptable safety profile among patients with R/R CD20-positive follicular lymphoma.
True or False: According to a phase 2 trial, the combination of amulirafusp alfa and lenalidomide demonstrated encouraging early clinical activity and an acceptable safety profile among patients with R/R CD20-positive follicular lymphoma.
True or False: According to a...
09/24/2025
Oncology
Quiz
Tocilizumab Plus Gemcitabine and Nab-Paclitaxel for Patients With Advanced Pancreatic Cancer
09/23/2025
In the phase 2 PATCO trial assessing the addition of tocilizumab to gemcitabine plus nab-paclitaxel among patients with advanced pancreatic cancer, which statement best reflects the implications for clinical practice?
In the phase 2 PATCO trial assessing the addition of tocilizumab to gemcitabine plus nab-paclitaxel among patients with advanced pancreatic cancer, which statement best reflects the implications for clinical practice?
In the phase 2 PATCO trial...
09/23/2025
Oncology
Quiz
Pomalidomide-Based Regimen for Multiple Myeloma Treatment
09/19/2025
True or False: For patients with first-relapsed multiple myeloma, the addition of pomalidomide to bortezomib and dexamethasone demonstrated a significantly worse progression-free survival and overall response rate compared with control...
True or False: For patients with first-relapsed multiple myeloma, the addition of pomalidomide to bortezomib and dexamethasone demonstrated a significantly worse progression-free survival and overall response rate compared with control...
True or False: For patients with...
09/19/2025
Oncology
Quiz
Atypical Characteristics of Small Cell Lung Cancer
09/18/2025
Dr Fawzi Abu Rous discussed the treatment of a 54-year-old patient who was diagnosed with an atypical case of small cell lung cancer. Which of the following features made this case atypical?
Dr Fawzi Abu Rous discussed the treatment of a 54-year-old patient who was diagnosed with an atypical case of small cell lung cancer. Which of the following features made this case atypical?
Dr Fawzi Abu Rous discussed the...
09/18/2025
Oncology
Quiz
Ruxolitinib Combined With Novel Agents for the Treatment of MF
09/12/2025
True or False: According to results from the ADORE clinical trial, ruxolitinib combined with siremadlin treatment demonstrated the least promising safety and efficacy for patients with myelofibrosis, compared with other novel agents in...
True or False: According to results from the ADORE clinical trial, ruxolitinib combined with siremadlin treatment demonstrated the least promising safety and efficacy for patients with myelofibrosis, compared with other novel agents in...
True or False: According to...
09/12/2025
Oncology
Quiz
Allogeneic Stem Cell Transplantation for R/R CLL
09/11/2025
True or False: For patients with high-risk or R/R chronic lymphocytic leukemia, including those previously treated with pathway inhibitors, allogeneic hematopoietic stem cell transplantation demonstrated improved outcomes.
True or False: For patients with high-risk or R/R chronic lymphocytic leukemia, including those previously treated with pathway inhibitors, allogeneic hematopoietic stem cell transplantation demonstrated improved outcomes.
True or False: For patients with...
09/11/2025
Oncology
Quiz
Patient Population Eligible for Zenocutuzumab
08/28/2025
Do you know the specific patient population for which zenocutuzumab is FDA-approved? Test your knowledge with our quick quiz.
Do you know the specific patient population for which zenocutuzumab is FDA-approved? Test your knowledge with our quick quiz.
Do you know the specific patient...
08/28/2025
Oncology

Recent News

News
Genotype-Guided Therapy Demonstrates High Response and Survival Rates for Patients With R/R DLBCL
09/26/2025
Emily Estrada
The implementation of R-ICE combined with genotype-guided therapy for the treatment of relapsed/refractory diffuse large B-cell lymphoma demonstrated clinical efficacy and safety in a phase 2 trial.
The implementation of R-ICE combined with genotype-guided therapy for the treatment of relapsed/refractory diffuse large B-cell lymphoma demonstrated clinical efficacy and safety in a phase 2 trial.
The implementation of R-ICE...
09/26/2025
Oncology
News
PD-1/PD-L1 Inhibitor Monotherapy Demonstrates Accceptable Safety, Limited Efficacy for R/R DLBCL
09/26/2025
Emily Estrada
Treatment of R/R diffuse large B-cell lymphoma with PD-1/PD-L1 inhibitors alone showed consistent safety but limited efficacy, while combination treatment with CAR T-cell therapy demonstrated potential improved outcomes.
Treatment of R/R diffuse large B-cell lymphoma with PD-1/PD-L1 inhibitors alone showed consistent safety but limited efficacy, while combination treatment with CAR T-cell therapy demonstrated potential improved outcomes.
Treatment of R/R diffuse large...
09/26/2025
Oncology
News
Polatuzumab-Based Regimens Demonstrate Promising Efficacy for R/R DLBCL Compared to Traditional Salvage Therapies
09/26/2025
Emily Estrada
Compared with traditional salvage therapies, polatuzumab vedotin and zanubrutinib combined with rituximab or obinutuzumab demonstrated encouraging clinical efficacy for patients with relapsed/refractory diffuse large B-cell lymphoma.
Compared with traditional salvage therapies, polatuzumab vedotin and zanubrutinib combined with rituximab or obinutuzumab demonstrated encouraging clinical efficacy for patients with relapsed/refractory diffuse large B-cell lymphoma.
Compared with traditional...
09/26/2025
Oncology
FDA Approval
FDA Approves Imlunestrant for Patients With ER-Positive, HER2-Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer
09/25/2025
Stephanie Holland
The FDA has approved imlunestrant for patients with ER-positive, HER2-negative advanced or metastatic breast cancer harboring ESR1 mutations.
The FDA has approved imlunestrant for patients with ER-positive, HER2-negative advanced or metastatic breast cancer harboring ESR1 mutations.
The FDA has approved...
09/25/2025
Oncology
News
Pexidartinib Shows Durable Response Among Patients with Tenosynovial Giant Cell Tumors
09/25/2025
Allison Casey
Pexidartinib showed sustained clinical benefit among patients with tenosynovial giant cell tumor associated with severe morbidity or functional limitations and not amenable to surgery.
Pexidartinib showed sustained clinical benefit among patients with tenosynovial giant cell tumor associated with severe morbidity or functional limitations and not amenable to surgery.
Pexidartinib showed sustained...
09/25/2025
Oncology
News
Clarithromycin-Based Quadruplet Therapy Demonstrates Promising Clinical Responses for Treatment of Relapsed/Refractory Multiple Myeloma
09/24/2025
Emily Estrada
For patients with relapsed/refractory multiple myeloma, the combination of clarithromycin, ixazomib, pomalidomide, and dexamethasone demonstrated promising clinical efficacy and a manageable safety profile.
For patients with relapsed/refractory multiple myeloma, the combination of clarithromycin, ixazomib, pomalidomide, and dexamethasone demonstrated promising clinical efficacy and a manageable safety profile.
For patients with...
09/24/2025
Oncology
News
First-Line mFOLFIRINOX, S-IROX Fail to Improve Survival Among Patients With Recurrent or Metastatic Pancreatic Cancer
09/23/2025
Stephanie Holland
Results from the phase 2/3 GENERATE study demonstrated that neither mFOLFIRINOX nor S-IROX improved survival results compared to nab-paclitaxel plus gemcitabine among patients with recurrent or metastatic pancreatic cancer in the first-line...
Results from the phase 2/3 GENERATE study demonstrated that neither mFOLFIRINOX nor S-IROX improved survival results compared to nab-paclitaxel plus gemcitabine among patients with recurrent or metastatic pancreatic cancer in the first-line...
Results from the phase 2/3...
09/23/2025
Oncology
News
Novel Anti-CSF1 Receptor Antibody for Patients With Tenosynovial Giant Cell Tumor
09/23/2025
Allison Casey
According to a phase 2a trial, the novel anti-CSF1 receptor monoclonal antibody, AMB-05X, was found to have favorable pharmacokinetics, pharmacodynamics, efficacy, and safety among patients with tenosynovial giant cell tumors.
According to a phase 2a trial, the novel anti-CSF1 receptor monoclonal antibody, AMB-05X, was found to have favorable pharmacokinetics, pharmacodynamics, efficacy, and safety among patients with tenosynovial giant cell tumors.
According to a phase 2a trial,...
09/23/2025
Oncology
News
Adverse Events With Pexidartinib for Patients With Tenosynovial Giant Cell Tumor
09/23/2025
Allison Casey
According to an analysis of the FDA Adverse Events Reporting System (FAERS) database, the overall safety profile of pexidartinib was generally consistent with the clinical trial findings.
According to an analysis of the FDA Adverse Events Reporting System (FAERS) database, the overall safety profile of pexidartinib was generally consistent with the clinical trial findings.
According to an analysis of the...
09/23/2025
Oncology
News
Trifluridine/Tipiracil Plus Bevacizumab Escalation Demonstrates Promise Among Patients With Advanced or Unresectable Metastatic Colorectal Cancer
09/22/2025
Stephanie Holland
According to results from the phase 2 E-BiTS study, intrapatient escalation of biweekly trifluridine/tipiracil plus bevacizumab demonstrated promising efficacy and safety among patients with advanced or unresectable metastatic colorectal...
According to results from the phase 2 E-BiTS study, intrapatient escalation of biweekly trifluridine/tipiracil plus bevacizumab demonstrated promising efficacy and safety among patients with advanced or unresectable metastatic colorectal...
According to results from the...
09/22/2025
Oncology

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use